Amiloride-quinidine interaction: Adverse outcomes

Li Wang, Robert S. Sheldon, L. Brent Mitchell, D. George Wyse, Anne M. Gillis, Nipavan Chiamvimonvat, Henry J. Duff

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives: Previous studies have reported beneficial antiarrhythmic effects when selected drugs were combined. The purpose of this study was to assess whether a favorable interaction would occur with amiloride and quinidine. Design: The antiarrhythmic and electrophysiologic effects of quinidine alone and in combination with amiloride were assessed in 10 patients with inducible sustained ventricular tachycardia. Parallel electrophysiologic studies assessed this drug combination in guinea pig papillary muscle. Results: None of the patients had adverse effects during quinidine monotherapy. However, seven of 10 patients had adverse responses to the combination treatment: three patients had suppression of inducible ventricular tachycardia during quinidine monotherapy but had sustained ventricular tachycardia induced during combination treatment; three other patients had somatic side effects that resulted in discontinuation of the combination therapy but were absent during quinidine monotherapy; and one patient had 12 episodes of sustained ventricular tachycardia during this combination therapy. The patient had no such response during monotherapy. Surface QRS duration was significantly more prolonged during combination therapy than during monotherapy. Parallel electrophysiologic effects assessed this drug combination in guinea pig papillary muscle. The combination of amiloride (1 μmol/L) and quinidine (10 μmol/L) synergistically decreased the maximum rate of rise of phase 0 of the action potential (V̇max) (43 ± 12 V/sec) compared with quinidine alone (24 ± 9 V/sec) because of a greater degree of tonic block of V̇max (14% ± 6%) as compared to quinidine alone (3% ± 3%) with no significant change in action potential duration. Conclusions: Amiloride exaggerates the effects of quinidine on QRS duration in patients and on V̇max during in vitro study, which implies that the proarrhythmic effect of the combination of amiloride and quinidine may be associated with synergistic increase in sodium channel blockade.

Original languageEnglish (US)
Pages (from-to)659-667
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume56
Issue number6
StatePublished - Dec 1994
Externally publishedYes

Fingerprint

Quinidine
Amiloride
Ventricular Tachycardia
Papillary Muscles
Drug Combinations
Action Potentials
Guinea Pigs
Therapeutics
Sodium Channels

ASJC Scopus subject areas

  • Pharmacology

Cite this

Wang, L., Sheldon, R. S., Mitchell, L. B., Wyse, D. G., Gillis, A. M., Chiamvimonvat, N., & Duff, H. J. (1994). Amiloride-quinidine interaction: Adverse outcomes. Clinical Pharmacology and Therapeutics, 56(6), 659-667.

Amiloride-quinidine interaction : Adverse outcomes. / Wang, Li; Sheldon, Robert S.; Mitchell, L. Brent; Wyse, D. George; Gillis, Anne M.; Chiamvimonvat, Nipavan; Duff, Henry J.

In: Clinical Pharmacology and Therapeutics, Vol. 56, No. 6, 12.1994, p. 659-667.

Research output: Contribution to journalArticle

Wang, L, Sheldon, RS, Mitchell, LB, Wyse, DG, Gillis, AM, Chiamvimonvat, N & Duff, HJ 1994, 'Amiloride-quinidine interaction: Adverse outcomes', Clinical Pharmacology and Therapeutics, vol. 56, no. 6, pp. 659-667.
Wang L, Sheldon RS, Mitchell LB, Wyse DG, Gillis AM, Chiamvimonvat N et al. Amiloride-quinidine interaction: Adverse outcomes. Clinical Pharmacology and Therapeutics. 1994 Dec;56(6):659-667.
Wang, Li ; Sheldon, Robert S. ; Mitchell, L. Brent ; Wyse, D. George ; Gillis, Anne M. ; Chiamvimonvat, Nipavan ; Duff, Henry J. / Amiloride-quinidine interaction : Adverse outcomes. In: Clinical Pharmacology and Therapeutics. 1994 ; Vol. 56, No. 6. pp. 659-667.
@article{2f14bde292894ddc94068ceec1121213,
title = "Amiloride-quinidine interaction: Adverse outcomes",
abstract = "Objectives: Previous studies have reported beneficial antiarrhythmic effects when selected drugs were combined. The purpose of this study was to assess whether a favorable interaction would occur with amiloride and quinidine. Design: The antiarrhythmic and electrophysiologic effects of quinidine alone and in combination with amiloride were assessed in 10 patients with inducible sustained ventricular tachycardia. Parallel electrophysiologic studies assessed this drug combination in guinea pig papillary muscle. Results: None of the patients had adverse effects during quinidine monotherapy. However, seven of 10 patients had adverse responses to the combination treatment: three patients had suppression of inducible ventricular tachycardia during quinidine monotherapy but had sustained ventricular tachycardia induced during combination treatment; three other patients had somatic side effects that resulted in discontinuation of the combination therapy but were absent during quinidine monotherapy; and one patient had 12 episodes of sustained ventricular tachycardia during this combination therapy. The patient had no such response during monotherapy. Surface QRS duration was significantly more prolonged during combination therapy than during monotherapy. Parallel electrophysiologic effects assessed this drug combination in guinea pig papillary muscle. The combination of amiloride (1 μmol/L) and quinidine (10 μmol/L) synergistically decreased the maximum rate of rise of phase 0 of the action potential (V̇max) (43 ± 12 V/sec) compared with quinidine alone (24 ± 9 V/sec) because of a greater degree of tonic block of V̇max (14{\%} ± 6{\%}) as compared to quinidine alone (3{\%} ± 3{\%}) with no significant change in action potential duration. Conclusions: Amiloride exaggerates the effects of quinidine on QRS duration in patients and on V̇max during in vitro study, which implies that the proarrhythmic effect of the combination of amiloride and quinidine may be associated with synergistic increase in sodium channel blockade.",
author = "Li Wang and Sheldon, {Robert S.} and Mitchell, {L. Brent} and Wyse, {D. George} and Gillis, {Anne M.} and Nipavan Chiamvimonvat and Duff, {Henry J.}",
year = "1994",
month = "12",
language = "English (US)",
volume = "56",
pages = "659--667",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Amiloride-quinidine interaction

T2 - Adverse outcomes

AU - Wang, Li

AU - Sheldon, Robert S.

AU - Mitchell, L. Brent

AU - Wyse, D. George

AU - Gillis, Anne M.

AU - Chiamvimonvat, Nipavan

AU - Duff, Henry J.

PY - 1994/12

Y1 - 1994/12

N2 - Objectives: Previous studies have reported beneficial antiarrhythmic effects when selected drugs were combined. The purpose of this study was to assess whether a favorable interaction would occur with amiloride and quinidine. Design: The antiarrhythmic and electrophysiologic effects of quinidine alone and in combination with amiloride were assessed in 10 patients with inducible sustained ventricular tachycardia. Parallel electrophysiologic studies assessed this drug combination in guinea pig papillary muscle. Results: None of the patients had adverse effects during quinidine monotherapy. However, seven of 10 patients had adverse responses to the combination treatment: three patients had suppression of inducible ventricular tachycardia during quinidine monotherapy but had sustained ventricular tachycardia induced during combination treatment; three other patients had somatic side effects that resulted in discontinuation of the combination therapy but were absent during quinidine monotherapy; and one patient had 12 episodes of sustained ventricular tachycardia during this combination therapy. The patient had no such response during monotherapy. Surface QRS duration was significantly more prolonged during combination therapy than during monotherapy. Parallel electrophysiologic effects assessed this drug combination in guinea pig papillary muscle. The combination of amiloride (1 μmol/L) and quinidine (10 μmol/L) synergistically decreased the maximum rate of rise of phase 0 of the action potential (V̇max) (43 ± 12 V/sec) compared with quinidine alone (24 ± 9 V/sec) because of a greater degree of tonic block of V̇max (14% ± 6%) as compared to quinidine alone (3% ± 3%) with no significant change in action potential duration. Conclusions: Amiloride exaggerates the effects of quinidine on QRS duration in patients and on V̇max during in vitro study, which implies that the proarrhythmic effect of the combination of amiloride and quinidine may be associated with synergistic increase in sodium channel blockade.

AB - Objectives: Previous studies have reported beneficial antiarrhythmic effects when selected drugs were combined. The purpose of this study was to assess whether a favorable interaction would occur with amiloride and quinidine. Design: The antiarrhythmic and electrophysiologic effects of quinidine alone and in combination with amiloride were assessed in 10 patients with inducible sustained ventricular tachycardia. Parallel electrophysiologic studies assessed this drug combination in guinea pig papillary muscle. Results: None of the patients had adverse effects during quinidine monotherapy. However, seven of 10 patients had adverse responses to the combination treatment: three patients had suppression of inducible ventricular tachycardia during quinidine monotherapy but had sustained ventricular tachycardia induced during combination treatment; three other patients had somatic side effects that resulted in discontinuation of the combination therapy but were absent during quinidine monotherapy; and one patient had 12 episodes of sustained ventricular tachycardia during this combination therapy. The patient had no such response during monotherapy. Surface QRS duration was significantly more prolonged during combination therapy than during monotherapy. Parallel electrophysiologic effects assessed this drug combination in guinea pig papillary muscle. The combination of amiloride (1 μmol/L) and quinidine (10 μmol/L) synergistically decreased the maximum rate of rise of phase 0 of the action potential (V̇max) (43 ± 12 V/sec) compared with quinidine alone (24 ± 9 V/sec) because of a greater degree of tonic block of V̇max (14% ± 6%) as compared to quinidine alone (3% ± 3%) with no significant change in action potential duration. Conclusions: Amiloride exaggerates the effects of quinidine on QRS duration in patients and on V̇max during in vitro study, which implies that the proarrhythmic effect of the combination of amiloride and quinidine may be associated with synergistic increase in sodium channel blockade.

UR - http://www.scopus.com/inward/record.url?scp=0028597914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028597914&partnerID=8YFLogxK

M3 - Article

C2 - 7995008

AN - SCOPUS:0028597914

VL - 56

SP - 659

EP - 667

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -